Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List

Stock News

2025/12/08

Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as "Jinpei Growth Hormone Injection") and the co-introduced Meishiya (commonly known as "Megestrol Acetate Oral Suspension").

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1153111707"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153111707\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153111707?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153111707","market":"other","top_or_hot":-1,"title":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List","media":"Stock News","content":"<p>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) Subsidiary Has Two Drugs Newly Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 16:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1153111707","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153111707","pubTimestamp":1765184295,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0239":"医药制造","BK0075":"新三板","BK0057":"长吉图板块","BK0188":"融资融券","000661":"长春高新","BK0046":"生物疫苗","BK0028":"国家队"},"translate_title":"长春高新技术产业（集团）有限责任公司。（000661.SZ）子公司有两种药品新纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91272":1,"000661":1},"content_text":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that, according to the \"National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)\" issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, two drugs from its subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as \"Jinsai Pharmaceutical\") have been newly included in the National Reimbursement Drug List. These include the self-developed Jinsaizeng (now commonly known as \"Jinpei Growth Hormone Injection\") and the co-introduced Meishiya (commonly known as \"Megestrol Acetate Oral Suspension\").","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}